Replimune Group Inc (NAS:REPL)
$ 7.9 0.79 (11.11%) Market Cap: 485.18 Mil Enterprise Value: 140.38 Mil PE Ratio: 0 PB Ratio: 1.30 GF Score: 30/100

Replimune Group Inc Virtual Investor Event Corporate Call Transcript

Jun 03, 2021 / 12:00PM GMT
Release Date Price: $31.9 (-12.00%)
Philip Astley;Sparke
Replimune Group, Inc. - CEO & Director

Good morning, and thank you for joining our midyear data update event. And before we begin, I need to highlight our forward-looking statement on Slide 2. I'm Philip Astley-Sparke, CEO of Replimune. And I have with me today, Dr. Robert Coffin, our President and Chief R&D Officer; we also have Dr. Mark Middleton, Professor of Experimental Cancer Medicine and Consultant Medical Oncologist at the Oxford Cancer Center and the Head of the Department of Oncology at the University of Oxford.

Slide 3 shows the agenda for the call, which will start with a brief [berth] introduction from me and a brief summary of the high level updated results by Rob, followed by discussion of the results in number of the individual patients by Dr. Middleton. Rob will then provide an overview of what will be one strand of our future development efforts with RP2, 3.

Following the presentation, we'll be holding a live Q&A. To ask a question, please type your question and click submit in the Q&A section on the bottom of your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot